Sales Channels and Strategies - The company has two main sales channels: hospital clinical sales for high-value consumables and home medical devices sold through pharmacies and e-commerce [1] - E-commerce has rapidly developed over the past two years, becoming a significant growth point for the company's external sales channels [1] - The company has strengthened control over terminal sales, including personnel deployment, sales expenses, and brand promotion [1] E-commerce Impact - The impact of online product sales prices on offline prices is minimal due to strict product differentiation and price control across various platforms [2] - New models are specifically designed for online sales, avoiding price conflicts with offline products [2] Medical Cloud Development - The medical cloud platform, launched in May, has seen significant growth, with user numbers increasing geometrically after the introduction of excellent physicians [2] - The focus is on user tracking and maintenance to ensure high-quality service, with plans to expand chronic disease management services [2] Acquisition and Operational Efficiency - Following the acquisition of Shanghai Medical Device Group, there have been no major changes to the management team [3] - Future efforts will focus on cost reduction, employee incentives, and product structure enhancement to improve overall competitiveness [3] New Product Development - The company is cautious about promoting new products, including the recently launched sleep apnea machine, which utilizes leading international technology [3] - The product is expected to grow alongside the market, targeting both personal and medical fields [3] Non-Public Offering Progress - The company's non-public offering application was submitted in August and has been accepted by the China Securities Regulatory Commission, with no recent updates available [3]

Group 1: Company Performance - The integration of Shanghai Medical Equipment Group is progressing smoothly, with the company returning to normal operations. The revenue for the first half of the year was approximately 300 million, with a net profit of over 30 million, meeting expectations [1] - The employee stock ownership plan was completed in the first half of the year, providing motivation for key personnel within the group [1] Group 2: Product Promotion and Market Demand - The dispersed oxygen machine is targeted for high-altitude areas, with current promotions focused on the Tibet market. There is strong demand from military, government agencies, enterprises, and hotels [2] - The company has completed the installation of oxygen equipment in 22 four-star hotels in Lhasa, which will be fully operational by late August [2] Group 3: Sales and Market Potential - The sleep apnea machine, launched in the second half of 2015, has monthly sales exceeding 1,000 units. In the U.S., the market for sleep apnea machines is larger than that for oxygen machines, but the Chinese market is still in its early stages, showing a trend of continuous growth [2] Group 4: Future Strategy - The company's future strategic direction is clear, focusing on home healthcare, clinical medicine, quality of life, and internet healthcare. Growth will be driven by both organic growth and external acquisitions [2]

编号：2021-07-05 证券代码：002223 证券简称：鱼跃医疗 江苏鱼跃医疗设备股份有限公司投资者关系活动记录表 | --- | --- | |-----------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...